The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization
Open Access
- 1 January 2010
- journal article
- Published by Springer Nature in Molecular Cancer
- Vol. 9 (1) , 19
Abstract
Nelfinavir is an HIV protease inhibitor that has been used for a long period of time to treat HIV-infected individuals. It has recently emerged that nelfinavir could represent a prospective new anti-cancer drug, prompting us to test the effect of nelfinavir on leukemia cells.Keywords
This publication has 36 references indexed in Scilit:
- Nelfinavir/ritonavir reduces acinar injury but not inflammation during mouse caerulein pancreatitisAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2009
- Role of RAF/MEK/ERK pathway, p‐STAT‐3 and Mcl‐1 in sorafenib activity in human pancreatic cancer cell linesJournal of Cellular Physiology, 2009
- Anti-HIV drugs for cancer therapeutics: back to the future?The Lancet Oncology, 2009
- Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humansCancer Biology & Therapy, 2008
- How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?Trends in Cell Biology, 2008
- HIV Protease Inhibitors Impact on ApoptosisMedicinal Chemistry, 2008
- HIV-1 Protease Inhibitors Nelfinavir and Atazanavir Induce Malignant Glioma Death by Triggering Endoplasmic Reticulum StressCancer Research, 2007
- HIV protease inhibitors modulate apoptosis signaling in vitro and in vivoApoptosis, 2007
- Microarray Analysis Reveals Glucocorticoid-Regulated Survival Genes That Are Associated With Inhibition of Apoptosis in Breast Epithelial CellsCancer Research, 2004
- MCL-1S, a Splicing Variant of the Antiapoptotic BCL-2 Family Member MCL-1, Encodes a Proapoptotic Protein Possessing Only the BH3 DomainJournal of Biological Chemistry, 2000